Literature DB >> 21692693

Multifunctional vaccines in cancer: the 'triad' approach.

John Nemunaitis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692693     DOI: 10.1586/erv.11.78

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  4 in total

1.  Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

Authors:  Neil Senzer; Minal Barve; Joseph Kuhn; Anton Melnyk; Peter Beitsch; Martin Lazar; Samuel Lifshitz; Mitchell Magee; Jonathan Oh; Susan W Mill; Cynthia Bedell; Candice Higgs; Padmasini Kumar; Yang Yu; Fabienne Norvell; Connor Phalon; Nicolas Taquet; Donald D Rao; Zhaohui Wang; Chris M Jay; Beena O Pappen; Gladice Wallraven; F Charles Brunicardi; David M Shanahan; Phillip B Maples; John Nemunaitis
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 2.  Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.

Authors:  Maria-Cristina S Pranchevicius; Thiessa R Vieira
Journal:  Bioengineered       Date:  2013-04-22       Impact factor: 3.269

3.  ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.

Authors:  Rodney P Rocconi; Laura Stanbery; Min Tang; Adam Walter; Bradley J Monk; Thomas J Herzog; Robert L Coleman; Luisa Manning; Gladice Wallraven; Staci Horvath; Ernest Bognar; Neil Senzer; Scott Brun; John Nemunaitis
Journal:  Commun Med (Lond)       Date:  2022-08-29

4.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.